Statute Details
- Title: Medicines (Export Licence for Psychotropic Substances) Regulations
- Act Code: MA1975-RG9
- Legislative Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Chapter 176), Sections 22 and 74
- Citation: Rg 9; G.N. No. S 216/1994
- Current status: Current version as at 27 Mar 2026
- Key provisions (as provided): Regulations 1–6; Schedule defines “psychotropic substance” by reference
- Commencement: Not stated in the extract (but the Regulations were first issued in 1994 and later revised/amended)
- Most relevant sections for practice: Reg. 3 (licensing requirement), Reg. 4 (application), Reg. 5 (fee), Reg. 6 (penalty)
What Is This Legislation About?
The Medicines (Export Licence for Psychotropic Substances) Regulations (“Export Licence Regulations”) create a licensing control for the export of psychotropic substances and medicinal products that contain psychotropic substances from Singapore. In practical terms, the Regulations prohibit export unless the exporter holds a valid export licence for the specific consignment and exports strictly in accordance with the licence’s terms and conditions.
The Regulations sit within Singapore’s broader medicines regulatory framework under the Medicines Act. They address a specific risk area: psychotropic substances are commonly associated with controlled medical use but also with diversion and misuse. By requiring a licence before export, the licensing authority can manage and monitor outbound shipments, thereby supporting public health and enforcement objectives.
Although the Regulations are relatively short, they are operationally significant. For exporters—typically pharmaceutical companies, wholesalers, and logistics or trade compliance teams—the Regulations impose a “consignment-specific” compliance obligation. This means that it is not enough to have general authorisations; the exporter must ensure that the shipment is covered by a valid export licence and that the shipment matches the licence conditions.
What Are the Key Provisions?
1. Definitions (Regulation 2)
The Regulations define key terms that determine scope and compliance. “Export” is defined as taking or causing to be taken out of Singapore by land, air or water, otherwise than in transit. This distinction matters for trade flows: goods merely passing through Singapore as transit may fall outside the definition, whereas goods leaving Singapore for a destination outside Singapore will generally be “export” for these purposes.
“Export licence” means a licence granted by the licensing authority under regulation 4(2). “Psychotropic substance” is defined by reference to the Schedule. The Schedule is therefore central: it identifies which substances trigger the licensing regime. For practitioners, the Schedule is not a mere formality; it is the legal trigger for whether a substance (or a medicinal product containing it) is regulated under these Regulations.
2. Core prohibition: no export without a valid licence (Regulation 3)
Regulation 3 is the heart of the regime. It provides that a person must not export any consignment of either:
(a) a psychotropic substance; or
(b) a medicinal product containing any psychotropic substance,
unless both conditions are satisfied:
- (i) The person possesses a valid export licence for that consignment; and
- (ii) The export is in accordance with the terms and conditions specified in the export licence.
This is a strict compliance structure. The licence must be “valid” and must cover the “consignment” being exported. Additionally, even where a licence exists, the exporter must comply with its terms and conditions—meaning that deviations (for example, different quantities, different destinations, different packaging, or shipment timing inconsistent with licence conditions) can create regulatory and criminal exposure.
3. Application process and licensing discretion (Regulation 4)
Regulation 4 governs how an exporter obtains an export licence. Under regulation 4(1), an application must be made to the licensing authority in such form and manner as the licensing authority may require. This gives the authority procedural flexibility (for example, requiring specific documentation, declarations, or supporting evidence).
Under regulation 4(2), upon receipt of an application, the licensing authority may, in his discretion, grant an export licence subject to such terms and conditions as he thinks fit. Two practice points follow:
- Discretion: the authority is not obliged to grant a licence even if an application is complete. Practitioners should therefore treat the application as a substantive request subject to assessment.
- Conditions: the authority can impose terms and conditions. Exporters should read and operationalise these conditions into their shipping, documentation, and quality systems.
Because the Regulations do not specify the criteria for discretion in the extract, practitioners should consult the licensing authority’s published guidance, internal compliance expectations, and the Medicines Act framework. In practice, licensing decisions often consider factors such as legitimate medical use, destination controls, end-user information, and diversion risk.
4. Fee and no refund (Regulation 5)
Regulation 5 sets a fixed fee for an export licence: $111. It also states that there shall be no refund of any fee paid under these Regulations. For exporters, this means that administrative and compliance diligence is important before submitting an application, because unsuccessful outcomes or licence changes may not be financially recoverable.
5. Penalty for contravention (Regulation 6)
Regulation 6 creates criminal liability for non-compliance. Any person who contravenes or fails to comply with regulation 3 is guilty of an offence and is liable on conviction to a fine not exceeding $2,000 or imprisonment for a term not exceeding 6 months, or both.
From a legal risk perspective, the penalty provision underscores that the licensing requirement is not merely administrative. It is enforceable through criminal sanctions. Practitioners should therefore ensure that export documentation, internal approvals, and shipment execution are aligned with the licence. Where there is a compliance breach, the question of “who” is the “person” responsible may arise—depending on corporate structures, contractual arrangements, and who actually “exports” or causes export to occur.
How Is This Legislation Structured?
The Regulations are structured as a short set of provisions followed by a Schedule:
- Regulation 1 (Citation): provides the short title.
- Regulation 2 (Definitions): defines “export,” “export licence,” and “psychotropic substance” (by reference to the Schedule).
- Regulation 3 (Licence to export psychotropic substance): sets the prohibition and the conditions for lawful export.
- Regulation 4 (Application for export licence): describes how to apply and the licensing authority’s discretion to grant licences with conditions.
- Regulation 5 (Fee): sets the licence fee and states no refund.
- Regulation 6 (Penalty): provides criminal penalties for contravention.
- The Schedule: lists substances that qualify as “psychotropic substance” for the purposes of the Regulations.
Notably, the extract does not show additional procedural details beyond the general “form and manner” requirement in regulation 4(1). Practitioners should therefore treat the Regulations as the legal baseline and rely on the licensing authority’s application requirements and the Medicines Act regulatory ecosystem for operational detail.
Who Does This Legislation Apply To?
The Regulations apply to “a person” who exports (or causes export) from Singapore consignments that fall within regulation 3—namely psychotropic substances and medicinal products containing psychotropic substances. This can include corporate entities and individuals involved in the export process, depending on how “export” is carried out in fact.
Because the prohibition is tied to the act of exporting a consignment, the practical scope extends beyond the manufacturer to include parties who may be responsible for shipping and export compliance (for example, exporters of record, logistics providers acting as agents, and compliance officers who authorise shipments). However, the legal liability will ultimately depend on the facts and the role each party plays in the export transaction and whether they “contravene or fail to comply” with regulation 3.
Why Is This Legislation Important?
Even though the Export Licence Regulations are concise, they have outsized practical impact. They create a clear compliance gate: if a shipment contains a scheduled psychotropic substance (or a medicinal product containing one), the exporter must hold a valid export licence for that consignment and must comply with the licence conditions. This directly affects how companies structure their supply chain, documentation, and approvals.
For practitioners advising pharmaceutical clients, the Regulations raise several recurring issues:
- Substance classification: confirming whether the substance is on the Schedule and whether the product contains any scheduled psychotropic substance.
- Consignment coverage: ensuring the licence corresponds to the specific shipment (quantities, batch/lot, destination, and other licence conditions).
- Operational compliance: implementing controls so that the exported goods match the licence terms (to avoid “technical” breaches that still constitute contravention).
- Criminal exposure: recognising that non-compliance can lead to fines and imprisonment, which elevates the importance of compliance systems and evidence trails.
From an enforcement perspective, the licensing model supports traceability and oversight. The licensing authority’s discretion to impose conditions allows tailored controls based on risk factors, destination requirements, and the nature of the consignment. For exporters, this means that legal compliance is not only about obtaining a licence but also about maintaining fidelity to the licence’s conditions through the export lifecycle.
Related Legislation
- Medicines Act (Chapter 176) — authorising provisions in Sections 22 and 74
Source Documents
This article provides an overview of the Medicines (Export Licence for Psychotropic Substances) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.